Correction: The sorafenib anti-relapse effect after alloHSCT is associated with heightened alloreactivity and accumulation of CD8+PD-1+ (CD279+) lymphocytes in marrow

Ítems similars

• The sorafenib anti-relapse effect after alloHSCT is associated with heightened alloreactivity and accumulation of CD8+PD-1+ (CD279+) lymphocytes in marrow
  per: Lange, Andrzej, et al.
  Publicat: (2018)
• Anti-CMV-IgG Positivity of Donors Is Beneficial for alloHSCT Recipients with Respect to the Better Short-Term Immunological Recovery and High Level of CD4+CD25high Lymphocytes
  per: Jaskula, Emilia, et al.
  Publicat: (2015)
• Cytokine Overproduction and Immune System Dysregulation in alloHSCT and COVID-19 Patients
  per: Lange, Andrzej, et al.
  Publicat: (2021)
• Intra-bone donor lymphocyte infusion at relapse: clinical outcome is associated with presence of CD8+ cells in the marrow
  per: Lange, Andrzej, et al.
  Publicat: (2019)
• Luspatercept for the treatment of anemia in allo-HSCT for patients with hematological diseases
  per: Xiangke Xin, et al.
  Publicat: (2025-02-01)